Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association

Posted in Biotech by Medtech[y] Staff

October 30, 2019 • 2 min read

​Veracyte, Inc. (Nasdaq: VCYT) announced today that new data advancing the understanding of genomic alterations – specifically, NTRK, RET, BRAF and ALK fusions – that are targeted by new precision medicine therapies for thyroid cancer will be presented at the 89th Annual Meeting of the American Thyroid Association...

Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

Posted in Biotech by Medtech[y] Staff

October 30, 2019 • 2 min read

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing innovative therapies for people with ultra-rare debilitating, chronic neuromuscular and neurological diseases, today announced top-line results from CMS-001...

Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

Posted in Biotech by Medtech[y] Staff

October 29, 2019 • 2 min read

​Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate, tipifarnib, that show durable anti-tumor activity as a single agent in heavily pretreated patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC)...